Anxiolytic drugs.
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000873:Anthracenes / Q000627:therapeutic use; D014151:Anti-Anxiety Agents / Q000627:therapeutic use*; D000929:Antidepressive Agents, Tricyclic / Q000627:therapeutic use; D014150:Antipsychotic Agents / Q000627:therapeutic use; D001007:Anxiety / Q000188:drug therapy; D001463:Barbiturates / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D001569:Benzodiazepines / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D003863:Depression / Q000188:drug therapy; D006801:Humans; D008620:Meprobamate / Q000009:adverse effects / Q000627:therapeutic use
D000319:Adrenergic beta-Antagonists; D000873:Anthracenes; D014151:Anti-Anxiety Agents; D000929:Antidepressive Agents, Tricyclic; D014150:Antipsychotic Agents; D001463:Barbiturates; D001569:Benzodiazepines; D008620:Meprobamate